Cardiovascular (CV) RiskDACRANCT07629518
Democratizing Access to Cleaner Residential Air
A study testing Portable air purifiers with HEPA filtration in people with Cardiovascular (CV) Risk, run by Douglas Brugge.
Trial summary
The purpose of this research study is to determine whether the use of in-home air filtration to reduce exposure to air pollution benefits health. Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular (CV) Risk
- What is being tested?
- Portable air purifiers with HEPA filtration
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 66 participants
- Where
- No sites listed yet
- Study dates
- Sep 2026to May 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 40 years or older Speaks English, Vietnamese, and/or Chinese Cognitive capacity to respond to questionnaires Lives fulltime at the current address, adjacent (< 200 meters) to roadways with large traffic volumes Must have one or more risk factors (hypertension or elevated blood pressure, pre-diabetes or diabetes or elevated blood sugar levels, elevated cholesterol levels, body mass index 25 or greater)
Who cannot join
- Pregnant Works between the hours of 10 PM and 6 AM Sources of smoke in the living space (such as candles, incense, marijuana, wood stove, fireplace) almost every day/every day.
- Every day exposure to motor vehicle exhaust (from cars, trucks, buses, trains), including heavy street or highway traffic.
- Currently smoking or vaping Others smoking or vaping indoors, in the living space. Within the past 5 years, a diagnosis of heart attack, heart disease, stroke, blood clots or pulmonary embolism, cancer requiring surgery and/or chemo/radiation therapy
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The purpose of this research study is to determine whether the use of in-home air filtration to reduce exposure to air pollution benefits health.
Read the detailed description
Conduct a randomized crossover pilot trial with 66 participants to calculate preliminary effect size estimates to inform a larger crossover efficacy trial:
We will: 1) enroll 66 individuals living in low and high traffic areas in Hartford (N=44) and a highly polluted urban areas in Boston Chinatown (N=22); and 2) install full filtration DIYAPs and sham DIYAPs for 30 days each in a randomized crossover trial design with a 14-day wash-out in between; and 3) measure seated and ambulatory BP, administer the SF-12v2, the Trail Making Test Part B, collect blood, and measure both indoor and outdoor PM (in size bins).
- Conditions
- Cardiovascular (CV) Risk
- Being tested
- Portable air purifiers with HEPA filtration, Portable air purifiers without filtration (sham)
- Keywords
- air pollution, air purifiers, HEPA filtration, cardiovascular risk, biomarkers
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Portable air purifiers with HEPA filtrationOther
Portable air purifiers filter air and reduce exposure to air pollutants, in this case, airborne particulate matter
Portable air purifiers without filtration (sham)Other
Air purifiers with filters removed (sham)
| Study group | Role | What they receive |
|---|---|---|
| Active filtration | Experimental | Air purifiers with HEPA filters Receives: Other: Portable air purifiers with HEPA filtration |
| Sham filtration | Sham comparator | Air purifiers lacking HEPA filters Receives: Other: Portable air purifiers without filtration (sham) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood pressure
Periferal blood pressure, seated
Measured: Day 0, 30, 45, and 75
Secondary outcomes (1)
IL-1beta
Blood inflammatory biomarker
Measured: Day 0, 30, 45, and 75
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2026
- Study startSep 2026 (estimated)
- Primary completionMay 2028 (estimated)
- Study completionMay 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular (CV) RiskStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Double blind, randomized crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 66 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Douglas Brugge
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Sponsor-investigator, Douglas Brugge, UConn Health
- Investigators
- Doug M Brugge, Principal investigator, UConn Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07629518
- Sponsor's protocol ID
- 25-285-2
- Other IDs
- R34HL173375
- Acronym
- DACRA
- Status last verified
- Jun 2026
- First submitted
- 1 Jun 2026
- Last updated
- 5 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified data after analysis of the ooutcomes of the study are completed
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Democratizing Access to Cleaner Residential Air
- ClinicalTrials.gov ID
- NCT07629518
- Acronym / sponsor ID
- DACRA / 25-285-2
- Conditions
- Cardiovascular (CV) Risk
- Keywords
- air pollution, air purifiers, HEPA filtration, cardiovascular risk, biomarkers
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 66 participants (estimated)
- Lead sponsor
- Douglas BruggeUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- Sep 2026 (estimated)
- Primary completion
- May 2028 (estimated)
- Study completion
- May 2029 (estimated)
- First posted
- 5 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research study is to determine whether the use of in-home air filtration to reduce exposure to air pollution benefits health.
Detailed description
Conduct a randomized crossover pilot trial with 66 participants to calculate preliminary effect size estimates to inform a larger crossover efficacy trial:
We will: 1) enroll 66 individuals living in low and high traffic areas in Hartford (N=44) and a highly polluted urban areas in Boston Chinatown (N=22); and 2) install full filtration DIYAPs and sham DIYAPs for 30 days each in a randomized crossover trial design with a 14-day wash-out in between; and 3) measure seated and ambulatory BP, administer the SF-12v2, the Trail Making Test Part B, collect blood, and measure both indoor and outdoor PM (in size bins).
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Double blind, randomized crossover
| Arm | Type | Receives |
|---|---|---|
| Active filtration | Experimental | Other: Portable air purifiers with HEPA filtrationAir purifiers with HEPA filters |
| Sham filtration | Sham comparator | Other: Portable air purifiers without filtration (sham)Air purifiers lacking HEPA filters |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Age 40 years or older Speaks English, Vietnamese, and/or Chinese Cognitive capacity to respond to questionnaires Lives fulltime at the current address, adjacent (< 200 meters) to roadways with large traffic volumes Must have one or more risk factors (hypertension or elevated blood pressure, pre-diabetes or diabetes or elevated blood sugar levels, elevated cholesterol levels, body mass index 25 or greater)
Key exclusion criteria (3 listed)
- Pregnant Works between the hours of 10 PM and 6 AM Sources of smoke in the living space (such as candles, incense, marijuana, wood stove, fireplace) almost every day/every day.
- Every day exposure to motor vehicle exhaust (from cars, trucks, buses, trains), including heavy street or highway traffic.
- Currently smoking or vaping Others smoking or vaping indoors, in the living space. Within the past 5 years, a diagnosis of heart attack, heart disease, stroke, blood clots or pulmonary embolism, cancer requiring surgery and/or chemo/radiation therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Portable air purifiers with HEPA filtrationPortable air purifiers filter air and reduce exposure to air pollutants, in this case, airborne particulate matter | Other | Active filtration |
| Portable air purifiers without filtration (sham)Air purifiers with filters removed (sham) | Other | Sham filtration |
Primary outcome
Blood pressure
Time frame: Day 0, 30, 45, and 75
Periferal blood pressure, seated
1 secondary outcome
IL-1beta
Time frame: Day 0, 30, 45, and 75
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2026.
- Individual participant dataSharing planned: Yes. De-identified data after analysis of the ooutcomes of the study are completed
Related trials for Cardiovascular (CV) Risk
RecruitingObservational study
Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women
Cardiovascular (CV) Risk
Not yet recruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Obesity, Overweight
RecruitingObservational study
The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT
Cardiovascular Risk, Prostate Cancer
Not yet recruiting
Neqpiaput Iinruugut (Our Food Is Medicine): A Tribally Driven Food Sovereignty Intervention to Reduce Heart Disease Risk in Alaska Native Adults
Cardiovascular (CV) Risk
Recruiting
Weight Management After Cancer for Survivors in Rural Communities
Breast Cancer Survivorship, Weight Management
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Doug M Brugge principal investigator
UConn Health
Questions about this trial
What is this clinical trial studying?
A study testing Portable air purifiers with HEPA filtration in people with Cardiovascular (CV) Risk, run by Douglas Brugge.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Doug Brugge, PhD (18606748814, brugge@uchc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood pressure (time frame: Day 0, 30, 45, and 75). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2026.